Home > Insider Trading > Filing (0001104659-20-103494)

Filing Details

Accession Number:: 0001104659-20-103494
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-09-09 17:04:15
Reporting Period:: 2020-09-04

Accepted Time:: 2020-09-09 17:04:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1771917	Karuna Therapeutics Inc.	KRTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1245624	James Healy	Sofinnova Investments, Inc., 3000 Sand Hill Road, 4-250 Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-09-04	1,670	$70.12	1,887,272	No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.
Common Stock	Acquisiton	2020-09-04	45,317	$71.30	1,932,589	No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.
Common Stock	Acquisiton	2020-09-04	6,461	$72.73	1,939,050	No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.
Common Stock	Acquisiton	2020-09-04	8,330	$73.59	1,947,380	No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.
Common Stock	Acquisiton	2020-09-08	504	$73.00	1,947,884	No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.

Footnotes

The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $69.66 to $70.61, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (1) to this Form 4.
All shares held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X"), the general partner of SVP X, may be deemed to have sole voting power, and Dr. James I. Healy, Dr. Maha Katabi, and Dr. Michael F. Powell, the managing members of SM X, may be deemed to have shared power to vote these shares. Such individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $70.66 to $71.50, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $72.30 to $73.27, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $73.30 to $74.00, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (5) to this Form 4.